Sandra Milligan - 31 Mar 2022 Form 4 Insider Report for Organon & Co. (OGN)

Role
Head of Research & Development
Signature
/s/ Tarnetta V. Jones, as Attorney-in-Fact for Sandra Milligan
Issuer symbol
OGN
Transactions as of
31 Mar 2022
Net transactions value
$0
Form type
4
Filing time
04 Apr 2022, 18:06:52 UTC
Previous filing
02 Mar 2022
Next filing
03 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OGN Restricted Stock Units Award $0 +17,892 $0.000000 17,892 31 Mar 2022 Common Stock 17,892 Direct F1, F2
transaction OGN Stock Option (right to buy) Award $0 +55,114 $0.000000 55,114 31 Mar 2022 Common Stock 55,114 $34.93 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU.
F2 These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025.
F3 The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025.